Domestic Pharmaceutical

Over 133 million shares, or 5.7% of the paid-up capital, are being offered for Rs 1,850-1,950 to investors through a special block window

Ipca's first half performance holds testimony to its robust growth with India business growing in mid-teens

The industry performed better in 2018, in comparison, on a GST-impacted low base

Within the sector, there has been a buzz that the draft policy has been put in the cold storage because of opposition from industry

Relaunching older prescription drugs in the OTC space allows companies to overcome sluggish prescription growth and also extend life of mature brands